Serplulimab Combined with Chemotherapy in Patients with Resectable Esophageal Squamous Cell Carcinoma
Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Dec 20, 2022
Trial Information
Current as of January 16, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment approach for patients with resectable esophageal squamous cell carcinoma, a type of cancer that starts in the esophagus. The researchers want to find out if combining a medication called serplulimab, which helps boost the immune system, with chemotherapy (a common cancer treatment) can improve outcomes before surgery. The goal is to see if this combination can help shrink the tumors and reduce the chance of the cancer coming back after surgery.
To be eligible for the trial, participants must be between 18 and 75 years old, have a confirmed diagnosis of esophageal squamous cell carcinoma that can be surgically removed, and have no signs of cancer spreading to other parts of the body. They should also be in good overall health, as assessed by a doctor. Participants can expect to receive the combination treatment and will be monitored closely for its effectiveness and any side effects. This trial is important because it could lead to better treatment options for patients facing this challenging disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. signed informed consent;
- • 2. patients age 18 to 75 years old
- • 3. primary resectable, histologically confirmed esophageal squamous cell cancer;
- • 4. Esophageal squamous cell carcinoma the clinical stage was IIA-IVA (according to AJCC TNM stage, 8th edition).
- • 5. ECOG PS 0-1.
- • 6. No distant metastasis, the diseases could be resectable assessed by thoracic oncologist;
- Exclusion Criteria:
- • 1. with significant cardiovascular disease;
- • 2. current treatment with anti-viral therapy or HBV;
- • 3. Female patients who are pregnant or lactating;
- • 4. history of malignancy within 5 years prior to screening;
- • 5. active or history of autoimmune disease or immune deficiency;
- • 6. signs of distant metastases.
Trial Officials
Weilin Wang
Study Chair
2nd Affiliated Hospital, School of Medicine, Zhejiang University
About Second Affiliated Hospital, School Of Medicine, Zhejiang University
The Second Affiliated Hospital of Zhejiang University School of Medicine is a leading clinical research institution dedicated to advancing healthcare through innovative medical practices and rigorous scientific inquiry. With a robust infrastructure and a multidisciplinary team of experienced researchers and clinicians, the hospital is committed to conducting high-quality clinical trials that address critical health challenges. As an integral part of Zhejiang University, the hospital leverages academic expertise and cutting-edge technology to foster collaboration in research, education, and patient care, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, , China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials